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Abstract
Breast cancer (BC) is the most common form of carcinoma and a primary cause of mor-
bidity and mortality globally. Oxidative stress represents as an important factor in 
carcinogenesis and may play a role in initiation and progression of tumors. Oxidative 
stress–induced NO• damage to DNA includes a multitude of lesions, many of which are 
mutagenic and have multiple roles in cancer and aging. It is caused by an unfavorable bal-
ance between reactive oxygen species/reactive nitrogen species (ROS/RNS) and antioxi-
dant defenses. ROS/RNS are generated during normal cellular metabolism, as a result of 
the influence of various environmental factors, as well as during pathological processes. 
Nitric oxide (NO•) is a ubiquitous, short-lived free radical produced from L-arginine by 
nitric oxide synthases (NOSs), and isoforms of NOS exist, depending on the site of origin: 
endothelial (eNOS), neuronal (nNOS), mitochondrial (mtNOS), and inducible (iNOS). 
eNOS is responsible for the endothelial synthesis of NO• and has shown to modulate 
cancer-related events such as inflammation, angiogenesis, apoptosis, cell cycle, invasion, 
and metastasis. Genetic studies also showed that eNOS gene polymorphisms are associ-
ated with the development of breast cancer. Therefore, selective targeting of eNOS may 
prove a potential strategy for prevention and treatment of breast cancer.
Keywords: breast cancer, oxidative stress, nitric oxide, endothelial nitric oxide synthase, 
therapeutics
1. Introduction 
Cancer, a multifaceted disorder, represents one of the most important health problems world-
wide, with approximately 14 million new cases and 8.2 million cancer-related deaths every 
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year [1]. The transformation from a normal cell into a tumor cell is a multistage process, typi-
cally a progression from a precancerous lesion to malignant tumors.
Cancers originate from a single abnormal cell (clonal origin) with an altered DNA sequence 
(mutation). Successive rounds of mutation and selective expansion of these cells result in the 
formation of a tumor mass and leads to tumor growth and progression, which eventually 
breaks through the basal membrane barrier of surrounding tissues and spreads to other parts 
of the body (metastasis) (Figure 1).
Cancers may be classified by their primary site of origin such as brain cancer, oral cancer, lung 
cancer, prostate cancer, liver cancer, renal cell carcinoma (kidney cancer), breast cancer, etc.
Breast cancer is defined as a malignant growth that begins in the epithelium of the breast. It 
is estimated as one of the most commonly diagnosed cancers worldwide (11.9%) [2]. In India, 
breast cancer has overtaken cervical cancer and has become the most prevailing cancer among 
women [3]. The most frequent type of breast cancer is ductal carcinoma in situ (DCIS), which 
affects the cells of the milk ducts. Cancer that starts in lobes or lobules is called lobular carci-
noma in situ (LCIS); it is the second most common type of breast cancer. While rare breast can-
cer types include tubular, medullary, metaplastic, mucinous carcinoma, and Paget’s disease.
Breast cancer is a clinically heterogeneous disease. Breast cancer cells generally overexpress 
estrogen receptor (ER)/progesterone receptor (PR), and/or human epidermal growth factor-2 
(HER-2) receptor and lead to the tumor formation and progression. Thus, breast cancer can be 
classified into two subgroups on the basis of receptor status namely: (i) ER/PR positive (lumi-
nal A/B) and (ii) triple negative (ER, PR, and HER-2 negative) (basal-like) to know the prog-
nosis and clinical outcome of breast cancer (Figure 2). Early breast cancer usually does not 
cause symptoms. As the cancer grows, symptoms may include: lump in the armpit, change in 
the size, shape, or feel of the breast or nipples, nipple discharge, etc. Symptoms of advanced 
breast cancer may include: breast pain or discomfort, bone pain, skin ulcers, and weight loss.
Breast cancer etiology is complex and multifactorial where there is a strong interplay between 
genetic and environmental factors. The strongest nonmodifiable determinants of breast  cancer 
risk are female gender and age. Other risk factors associated with breast cancer can be grouped 
into three broad determinants: family history (hereditary) factors, hormonal and reproduc-
tive factors, and environmental (including lifestyle) factors (Figure 3).
Figure 1. Carcinogenesis, a multistep process.
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Figure 2. Classification of breast cancer.
Figure 3. Breast cancer etiology.
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Family history (hereditary) factors are associated primarily with early-onset of breast cancer. 
Previous genetic analyses of breast cancer–prone families have identified the BRCA1 and 
BRCA2 genes (breast cancer type 1 and 2 susceptibility protein). Women with mutations in 
either BRCA1 or BRCA2 (over 250 mutations have been identified) are at a significantly ele-
vated lifetime risk (55–85% compared with 12% for the general population) for developing 
breast or ovarian cancer [4].
Reproductive and hormonal factors may increase the time and/level of steroid hormone expo-
sure, consequently stimulating cell growth, and have been associated with breast cancer sus-
ceptibility. Major reproductive factors such as early menarche, late menopause, later age at 
first full-term pregnancy, and nulliparity are known to be associated with a higher risk of 
breast cancer [5].
Environmental (including lifestyle) factors such as the use of exogenous estrogens, radiation 
exposure, alcohol consumption, and socioeconomic status are also well-known risk factors 
for the disease [6]. Physical inactivity is a major risk factor for several types of cancer [7–
9]. Exposure to ionizing radiation such as X-rays at a young age, alcohol consumption, and 
smoking habits have consistently been shown to increase breast cancer risk.
Radiations are classified into two major types namely: ionizing radiation and nonionizing radi-
ation. The ionizing radiation transmits energy via X-rays and alpha particles disrupt chemical 
bonds, which results in chemically reactive free radical formation, a phenomenon known as ion-
ization. These ionizing radiations may directly pass through the cell and may cause DNA dam-
age. Such damage if unrepaired can result in nonlethal DNA modifications or cell death. The 
nonlethal DNA modifications thus eventually may cause malignant transformations. Ionizing 
radiation is, therefore, a known mutagen and an established breast carcinogen. Nonionizing 
radiation (e.g., microwaves and extremely low-frequency electric and magnetic fields (ELF-
EMF)) does not have enough energy to break chemical bonds and produce ionization [10].
Several epidemiological studies have shown that alcohol consumption has been associated 
with breast cancer susceptibility. The alcohol metabolism occurs via multiple stages which 
may increase the risk of carcinogenesis. Alcohol metabolized into an acetaldehyde and other 
products subsequently damages DNA by inducing DNA modifications. Apart from this, acet-
aldehyde alone may also cause breast tumorigenesis by interfering with DNA repair mecha-
nisms. Free radicals generated in the second stage of alcohol metabolism are thought to cause 
DNA damage, strand breakage, and base alterations and have been implicated for their role 
in alcohol-associated carcinogenesis [11].
There are over 60 carcinogens in cigarette smoke, which have been evaluated by the 
International Agency for Research on Cancer [12]. Cigarette smoke is rich in carcinogens such 
as nitrosamines and polycyclic aromatic hydrocarbons and induces oxidative damage. The 
gas phase of freshly generated cigarette smoke has large amounts of nitric oxide and other 
unstable oxidants. The presence of such free radicals and oxidants can lead to oxidative DNA 
damage [13]. The environmental risk factors that alter the levels of free radicals (reactive spe-
cies) generated in the body are known to react with DNA to cause mutations in critical genes 
and consequently promote carcinogenesis.
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2. Free radicals
Free radicals are molecules with high instability and reactivity due to the presence of an odd 
number of electrons in the outermost orbit of their atoms; their action derives from their 
attempts to attain “balance” by binding with electrons of neighboring atoms, giving rise to 
chain reactions (Figure 4) [14].
Free radical can be classified as reactive oxygen species (ROS) and reactive nitrogen species 
(RNS). ROS include the superoxide anion (O
2
−), hydroxyl radical (OH−), hydrogen peroxide 
(H
2
O
2
), while RNS include nitric oxide (NO•−) and peroxynitrite (ONOO−) the radical nitro-
gen dioxide (NO
2
−), and nitrite (NO
2
−) [15].
Free radicals are key players in the initiation and progression of tumor cells and enhance their 
metastatic potential. They are now considered a hallmark of cancer.
3. Oxidative stress
The cell generates free radicals and also degrades, which is strictly necessary to avoid the 
damage derived from free radicals. However, various intrinsic and extrinsic circumstances 
and the biochemical activity of the cell can make it lose control over the formation and man-
agement of free radicals and results in “oxidative stress.” It results from a disturbance in bal-
ance between the formation of ROS/RNS and the defense provided by cell antioxidants. This 
imbalance may cause damage related to various human diseases (Figure 5) [16].
During endogenous metabolic reactions, aerobic cells produce ROS such as superoxide anion 
(O
2
−), hydrogen peroxide (H
2
O
2
), hydroxyl radical (OH•), and organic peroxides as normal 
products of the biological reduction of molecular oxygen [17]. Under hypoxic conditions, the 
mitochondrial respiratory chain also produces nitric oxide (NO•−), which can generate other 
reactive nitrogen species (RNS) [18].
Figure 4. Formation and elimination of ROS.
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4. Antioxidants
Cells have natural defense systems against ROS that consist of antioxidant enzymes, vitamins, 
etc., some of these antioxidants are produced inside the human body, mostly falling into the 
enzymatic category, as they are predominantly protein in nature. These proteins include the 
superoxide dismutase (SOD) enzymes (which have differential subcellular localization and 
superoxide dismutation to H
2
O
2
), glutathione peroxidase (GPx), and catalase (both of which 
clear peroxide), thioredoxins (Trxs; reduce oxidized proteins), and glutathione synthetase 
(GSS; synthesizes glutathione [GSH], an important antioxidant), among others. Vitamins are 
mostly obtained from nutritional sources and include ascorbic acid (vitamin A), tocopherol. 
Therefore, a fine balance exists between the levels of ROS and antioxidants within the cell [19]. 
Increased ROS/RNS can result in a greater number of mutations, oxidation of critical proteins, 
and other alterations, finally culminating in cell death. Identification of potentially modifiable 
factors that affect oxidative stress in breast cancer patients is an increasingly important task.
5. Nitric oxide
Nitric oxide (NO•) is a ubiquitous, short-lived, water soluble and endogenously produced 
gas that exerts a wide range of biological effects. It is a pleiotropic regulator, critical to numer-
ous biological processes, including vasodilation, neurotransmission, and macrophage-medi-
ated immunity.
Figure 5. Oxidative stress.
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The general function of NO• protects against the effects of free radicals but at excessive con-
centrations, NO• or its derivatives may lead to DNA damage and impair the tumor suppres-
sor function of p53, which may cause cancer development [20].
5.1. Intracellular mechanisms of NO•−
When NO• is synthesized, it has a half-life of only a few seconds. Its bioavailability is reduced 
due to the high affinity binding of superoxide anion (high reactivity in both molecules is 
due to the unpaired electrons). NO• has an ability to tightly bind to the heme moiety of 
both hemoglobin (Hb) and guanylyl cyclase (GC) and found mostly in the vascular smooth 
muscle cells and other cells. Thus, NO• when produced in endothelium is quickly diffused 
into the blood circulation, binds to hemoglobin in blood and forms nitrates. NO• may also 
activate guanylyl cyclase (GC), an enzyme that catalyzes the dephosphorylation of guanosine 
triphosphate (GTP) to 3′,5′-cyclic guanosine monophosphate (cGMP) and serves as a second 
messenger for many important cellular functions, particularly for signaling smooth muscle 
relaxation [21].
5.2. NO•− biological functions
Nitric oxide (NO•−) is known to play important functional roles in a variety of physiological 
systems [22].
1. NO•− induces vasodilation—NO initiates and maintains vasodilation through a cascade of 
biological events that culminate in the relaxation of smooth muscle cells that line arteries, 
veins, lymphatics. NO also inhibits the aggregation of platelets and thus keeps inappropri-
ate clotting from interfering with blood flow.
2. NO•− regulates programmed cell death (apoptosis)—NO has been shown to both induce 
and inhibit apoptosis. The activity of the caspases can be directly affected by antiapop-
totic effects of NO through nitrosylation of the active site, leading to inhibition of protein 
function. NO can also affect the expression of many members of the Bcl-2 protein family, 
including both proapoptotic proteins.
3. NO•− alters kidney function—The release of NO around the glomeruli of the kidneys in-
creases blood flow through them thus increasing the rate of filtration and urine formation.
4. NO•− induces smooth muscle cell contractility—The relaxing effect of NO on the smooth 
muscle allows wavelike motions in the gastrointestinal tract.
While, NO also inhibits the contractility of the smooth muscle wall of the uterus. During child 
birth, as the moment of birth approaches the production of NO decreases.
5. NO•− affects secretion from several endocrine glands—NO regulates the release of Gon-
adotropin-releasing hormone (GnRH) from the hypothalamus and adrenaline from the 
adrenal medulla.
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In mammals, under normoxic conditions, NO• is generated endogenously “on demand” 
when the guanidino nitrogen of L-arginine undergoes a five-electron oxidation to yield the 
gaseous free radical, nitric oxide, and citrulline in equimolar concentrations (Figure 6) [23].
The constitutive forms of NOS are endothelial NOS (eNOS; type III) and inducible NOS 
(iNOS; type II). Cofactors for NOS include oxygen, NADPH, tetrahydrobiopterin, and flavin 
adenine nucleotides.
The inducible (calcium-independent) isoform (iNOS) produces much larger amounts of NO 
and is only expressed during inflammation. Whereas iNOS can produce injurious amounts 
of RNS (check), eNOS and nNOS produce beneficial amounts under physiological condi-
tions. The constitutive (calcium-dependent) isoform and endothelial NOS (eNOS) produce 
small amounts of NO, which act as a vasodilator. The third form, neural NOS (nNOS; type I) 
serves as a transmitter in the brain and in different nerves of the peripheral nervous system to 
produce vasodilation. mtNOS constitutively expressed and membrane-bound nNOS isoform 
alpha, precluding a novel alternative spliced product. The mitochondrial production of nitric 
oxide is catalyzed nitric-oxide synthase (mtNOS). This enzyme has the same cofactor and 
substrate requirements as other constitutive nitric-oxide synthases (Figure 6).
NOS1 is the neural (or brain) isoform, also known as nNOS. It plays an important role in neu-
ral communication via synaptic transmission from nerve to nerve across synapses, and from 
peripheral nerves to the brain.
NOS2 is also known as iNOS. It generates extremely elevated concentrations of NO, to partici-
pate in a host defense mechanism. It also takes several hours to be activated in response to an 
injury or infection. Unlike nNOS, which takes part in normal neural communication, an abnor-
mal stimulus (a wound, tissue damage, hypoxia, bacterial infection, etc.) may induce iNOS.
Figure 6. Mechanism of NO production from NOS.
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The third isoform is eNOS (or NOS3) which stands for “endothelial cell” NOS. This isoform 
is active at all times and is found in endothelial cells which are the cells that line the inner 
surface of all blood vessels and lymph ducts. The eNOS is activated by the pulsatile flow of 
blood through vessels and maintains the diameter of the blood vessels at an optimal level. In 
addition, it also promotes angiogenesis, a process of new blood vessels formation.
A fourth type, mitochondrial NOS (mtNOS), differentiated by its subcellular localization 
in the mitochondrial inner membrane, regulates various functions of mitochondria in liver, 
heart, kidney, breast, etc. The mitochondrial utilization of NO involves superoxide anion and 
H
2
O
2
, a species freely diffusible outside the mitochondria that participate in the modulation of 
cell proliferation and apoptosis and in cell transformation leading to cancer [24, 25].
6. Endothelial nitric oxide synthase (eNOS)
Endothelial nitric oxide synthase enzyme, also known as nitric oxide synthase-3 (NOS-3) or 
constitutive NOS (cNOS), has been shown to be a critical regulator of carcinogenesis. It is a 
dimeric structure in their active form containing two identical monomers of 134 kD repre-
sented by a reductase domain containing the binding sites for nicotinamide adenine dinucleo-
tide phosphate (NADPH), flavin mononucleotide (FMN), and flavin adenine dinucleotide 
(FAD). While an oxidase domain comprises the binding sites for the heme group, zinc, the cofac-
tor tetrahydrobiopterin (BH4), and the substrate L-arginine [26]. The reductase domain is 
attached to the oxidase domain via calmodulin-binding sequence [27].
The eNOS expression is regulated by a range of transcriptional and posttranscriptional 
mechanisms, generates nitric oxide (NO•) in response to a number of stimuli. Constitutively 
expressed eNOS oxidizes L-arginine to generate L-citrulline and NO•. The essential cofac-
tors for catalysis of this reaction include as calmodulin (CaM), flavin mononucleotide, flavin 
adenine dinucleotide, tetrahydrobiopterin (H4B) and NADPH.
Typically, the eNOS isoforms can be activated as a result of calmodulin (CaM) binding fol-
lowing a rise in intracellular calcium. They may also be activated and/or inhibited by phos-
phorylation via various protein kinases. Oxygen levels also regulate NOS levels in a cell type 
and isoform-specific manner by altering enzyme expression and by limiting the availability of 
oxygen, a key substrate for NO• synthesis.
Experimental and epidemiological evidence has shown the contributory role of eNOS induced 
NO• in tumor progression, suggesting a possible implication of endothelium expressed 
eNOS in tumors. The role of NO• in cancer biology is widespread, including its involvement 
in cellular transformation, malignant lesions, initiation, progression of the metastatic process, 
and induction of genotoxicity [28]. NO•-mediated DNA damage may be due to direct modi-
fication of DNA, or inhibition of DNA repair mechanisms [29]. Similarly, most of the RNS can 
cause DNA strand breaks and result in multiple mutations in DNA [30].
Breast carcinogenesis involves the transformation of a normal cell into a tumor cell mediated 
by a sequence of cellular and molecular events. These events consist of the attainment of 
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precise characteristics, such as uncontrolled proliferation, avoidance of mitotic control, resis-
tance to apoptosis, replicative immortality, escape from immune surveillance, progression 
by stimulating invasion and metastasis, angiogenesis, genomic instability, and deregulated 
metabolism [31].
Tumor-derived eNOS has shown to modulate cancer-related events (inflammation, apop-
tosis, cell cycle, angiogenesis, invasion, and metastasis) (Figure 7) and genetic studies 
showed that eNOS gene polymorphisms are associated with the development of multiple 
cancers [32].
6.1. Inflammation
Inflammation a localized protective response elicited by injury is known to cause DNA dam-
age [33]. Chronic inflammation due to infection or injury is estimated to contribute to 25% of 
all cancers in the world [34]. A growing body of laboratory research has shown that inflam-
mation is a key mediator in the promotion of malignant transformation, where pro-inflamma-
tory cytokines can facilitate tumor growth and metastasis by altering tumor cell biology and 
activating stromal cells in the tumor microenvironment, such as vascular endothelial cells, 
tumor-associated macrophages, and fibroblasts.
NO• is closely related to inflammatory status and regarded as a critical inflammation 
mediator. Pro-inflammatory cytokines can modulate the expression of eNOS and can accel-
erate the growth and development of cancer. eNOS, for example, can regulate the expres-
Figure 7. Multiple roles of eNOS in tumor development.
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sion of the pro-inflammatory molecules nuclear factor-κB (NF-κB) and cyclooxygenase-2 
[32, 35, 36].
6.2. Apoptosis
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and 
pathological conditions. Impaired apoptosis has been associated with initiation and develop-
ment of cancer. The mechanism of apoptosis is regulated by an array of factors triggering 
and activating signaling cascade, subsequently leading to cellular death [33]. eNOS may be 
a molecular node in growth factor–mediated inhibition of apoptosis [37]. The antiapoptotic 
mechanism is understood on the basis of gene transcription of protective proteins and direct 
inhibition of the apoptotic executive effectors (caspase family protease).
The mechanisms of action that lead to the proneoplastic activity of NO• are via apoptosis inhibi-
tion by S-nitrosylation-inactivation of caspases- 1, 2, 4, 8 and 3, 6, 7 and disruption of the apoptotic 
protease activating factor 1/caspase-9 complex (Apaf-1/caspase-9 apoptosome is an essential ini-
tiator of caspase activation that initiates an apoptotic protease cascade) [38]. Other antiapoptotic 
effects of NO• depends on the interaction of NO•/cGMP, which inhibits the release of cytochrome 
C, stimulation of heat-shock protein (Hsp) 70 and Hsp 32, elevated Bcl-2 expression, repression of 
ceramide generation [39], and induces cyclooxygenase-2 activity [40]. In the animal model study, 
the lipopolysaccharide (LPS)-induced hepatic apoptosis was increased by the administration of 
NOS inhibitors [41]. Thus at high concentration, NO• has a potential role in cancer, i.e., inhibition 
of eNOS activity specific to tumor cells may be a viable option for the stimulation of apoptosis 
and treatment of cancer alone or in combination with chemotherapeutic agents.
6.3. Angiogenesis
Angiogenesis in mammary tumors can be stimulated by inflammation, which induces pro-
liferation and morphogenesis of vascular endothelial cells in response to a large number 
of cytokines or angiogenic molecules produced by tumor and host cells [42]. Angiogenesis 
is essential for tumor growth and metastasis and has been considered the most important 
prognostic indicator for predicting overall survival [43]. eNOS strongly affects tumor growth 
by promoting angiogenesis [44]. Tumor growth–enhancing effects of vascular endothelial 
growth factor (VEGF) are associated with increased NOS activity and inhibition of apoptosis 
in human breast carcinoma xenografts [45].
Endogenous NO• promotes tumor blood flow via dilatation of arteriolar vessels. It decreases 
leukocyte-endothelial adhesive interactions and increases vascular permeability [46]. Several 
cancer treatment methods influence eNOS expression and activity. Low-dose irradiation-
induced angiogenesis is believed to be mediated by NO• from eNOS [47]. Studies have 
shown that VEGF released as a purified protein or produced by tumor cells requires a func-
tional NO•/cGMP pathway within the end compartment to promote neovascular growth. 
NO• also has an invasion-stimulating effect, which is mediated by upregulation of MMP-2 
and MMP-9 (matrix metalloproteinases) and downregulation of TIMP-2 and possibly TIMP-3 
(tissue inhibitors of MMP) [48].
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6.4. Tumor progression/invasion
NO• has been investigated regarding its possible involvement in the promotion of breast car-
cinoma. Increased amounts of NO• have been observed in the blood circulation of advanced 
grade breast cancer patients [49] where the increased levels of NO• have shown to promote 
tumor angiogenesis. Nitrotyrosine, a marker derived from NO•, was correlated with expres-
sion of VEGF-C and has been associated with lymph node metastasis in breast carcinoma 
patients, implicating the role of NO• in the development and progression of breast cancer 
[50]. In relation to the link of eNOS with cell proliferation, the eNOS expression has been 
detected in tumor cells specifically in breast cancer [51].
Several studies have observed NO• released by eNOS, can stimulate cancer cell cycle pro-
gression and proliferation. More specific to eNOS, studies have shown that the eNOS/NO• 
pathway plays a role in cancer cell DNA/RNA synthesis and proliferation apart from pro-
moting angiogenesis [52]. The eNOS gene plays an essential role in endothelial cell pro-
liferation in cell culture models and is a central mediator of several endothelium growth 
stimulators, such as vascular endothelial growth factor (VEGF) and prostaglandin E2. In 
human breast cancer, eNOS appears to be expressed in tumor epithelial cells, and its pres-
ence is correlated with histological grade and lymph node status. Higher NOS activity has 
been found in invasive breast tumors when compared with benign or normal breast tissue 
carcinoma [53].
6.5. Metastasis
Metastasis is a complex process by which the malignant cancer cells from the breast expand 
into other regions of the body. Lymphatic metastasis is a critical determinant of cancer prog-
nosis. Recent findings indicate that eNOS mediates VEGF-C-induced lymph-angiogenesis 
and, consequently, plays a critical role in lymphatic metastasis [54]. Investigational studies on 
tumors have provided substantial evidence of the contributory role of NO• in tumor devel-
opment, where series of tests were performed on tumor-bearing mice using NOS inhibitors 
showed a delayed tumor growth through eNOS inhibition and barred metastasis, signifying 
the potential role of endothelium-derived eNOS in metastasis [55].
7. Regulation OF NOS3 gene expression
The most fundamental level of NOS regulation is reflected in the tissue-specific expression of 
the different isoforms. The amount of NO produced results from the expression level and activ-
ity of eNOS. It is regulated by several interlinking mechanism such as transcriptional, post-
transcriptional, and posttranslational modifications. The activity of NOS3 is also controlled by 
avid binding transcription factors namely Ets-1, Elf-1, Sp1, Sp3, and YY1 to the NOS3 promoter 
region. Posttranscriptionally, NOS3 activity is controlled by modifications of the primary 
transcript, stability of mRNA, its subcellular localization, and nucleocytoplasmic transport. 
Posttranslational modifications of NOS3 consist of fatty acid acylation, substrate, and cofactor 
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availability, protein-protein interactions, and amount of phosphorylation. Another significant 
epigenetic mechanism for NOS3 gene expression is differential promoter methylation [47].
The gene-encoding eNOS located on chromosome 7q35-36 and is composed of 26 exons (cod-
ing sequences) and introns (sequences between exons) with an entire length of 21 kb and 
has more than 168 polymorphisms [56]. Over the last few years, polymorphisms of the gene 
have been identified, and their association with various diseases has been explored. Genetic 
comparison studies on healthy people and cancer patients have shown that polymorphisms 
in eNOS are associated with the development of cancers.
A single nucleotide polymorphism (SNP), T-786C, was identified in the 5′ flanking region 
involving a substitution of thymine (T) to cytosine (C) at a locus 786 base pairs upstream 
[57]. Another common variant of eNOS with a G to T transversion at nucleotide position 894 
(G894T) leading to a change in amino acid at 298 (Glu298Asp) has been reported [58], and a 
27-bp variable number of tandem repeats (VNTR) polymorphism in intron 4 (intron 4b/4a) 
[59] and high numbers of CA, which have been repeated in intron 13 of eNOS gene, are also 
known to be associated with complex disorders. These polymorphisms seem to be functional 
and have been widely investigated for their associations with cancer risk [60, 61]. Molecular 
studies of eNOS −786T > C, intron 4b/4a, and 894G > T polymorphisms (Figure 8) if performed 
in large and unbiased can provide valuable insights into the association between the eNOS 
gene and breast cancer risk.
8. Conclusion
All these findings suggest that the expression of eNOS in breast cancer may be a critical event 
in carcinogenesis. Understanding different actions of NO• induced by eNOS in breast cancer 
Figure 8. Organization of eNOS gene.
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at the molecular level can help in providing diagnostic or prognostic markers and also in 
devising potential strategies for prevention of breast cancer. The ability of many tumors to 
exploit eNOS/NO for a survival, proliferative, and metastatic advantage suggests that phar-
macological use of eNOS inhibitors might attenuate these effects. Therefore, selective target-
ing of eNOS may prove a useful therapeutic or chemopreventive measure. However, further 
careful studies are needed to confirm the potential therapeutic role of eNOS as a novel target 
for breast cancer therapy.
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